EyeBio

Closed

Developing a new generation of therapies to protect, restore, and improve vision

Subsidiary of Merck & Co.

Subsidiary of Merck & Co. · London, United Kingdom · Founded 2021 · $130.0M raised

Headquarters
London
Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$130.0M
Last Round
$65.0M Series ANov 2023
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

EyeBio (Eyebiotech Limited) is a privately held ophthalmology biotechnology company founded in 2021 and headquartered in London, UK, with additional operations in New York. Co-founded by Kate Bingham and Anthony Adamis and backed by SV Health Investors, EyeBio focuses on developing next-generation therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases. The company was acquired by Merck in July 2024 in a deal worth up to $3 billion, and now operates as a subsidiary within Merck's ophthalmology pipeline.

Summary

EyeBio is a Biotech company based in London, United Kingdom, founded in 2021. It has raised $130.0M in total across 2 rounds, most recently a $65.0M Series A round in Nov 2023. Investors include Bain Capital Life Sciences, Omega Funds and SV Health Investors.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries ANov 2023
$65.0M

Sign up to see all 2 events

Funding: Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

EyeBio on Indexed.vc
<a href="https://indexed.vc/companies/eyebio"><img src="https://indexed.vc/api/badge/company/eyebio" alt="EyeBio on Indexed.vc" width="260" height="76" /></a>